Eli Lilly shares were up by 0.22% to $746.04 on Wednesday at 1:13 pm. On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY ... not the investors who make buy and sell decisions). The stock is down 11.8% since reporting and currently trades at $743.98.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

Eli Lilly and Company (NYSE:LLY) is the second best stock that will always grow. Aristotle Atlantic Partners, LLC highlighted LLY in its Q4 2024 investor letter. Here is what the firm said ...

Eli Lilly ( LLY 2.92%) and Novo Nordisk ( NVO -0.89%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...